Stock BOLT BOLT BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Delayed Nasdaq
Other stock markets
 03:02:45 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.109 USD +0.84% Intraday chart for Bolt Biotherapeutics, Inc. -0.07% -0.96%
Mar. 21 Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 21 Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4
MT
Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating
MT
HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target
MT
Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating
MT
SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8
MT
Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating
MT
Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating
MT
Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating
MT
Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45
MT
Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating
MT
SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating
MT
BOLT BIOTHERAPEUTICS : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating
MT
BOLT BIOTHERAPEUTICS : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating
MT
BOLT BIOTHERAPEUTICS : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target
MT
BOLT BIOTHERAPEUTICS : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target
MT
BOLT BIOTHERAPEUTICS : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target
MT
BOLT BIOTHERAPEUTICS : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BOLT Stock
  4. News Bolt Biotherapeutics, Inc.
  5. Analyst Reco.